Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 31.08.2026 GMAY.LN IE000P0FL8E3 1,350,002.00 USD  54,969,984.53   40.718  ...

GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en Fujirebio, zijn dochteronderneming volledig in handen van het bedrijf, maakten vandaag bekend dat Health Canada Class II MDL's (Medical Device Licenses) heeft toegekend voor de Lumipulse G NfL Blood- en de Lumipulse G pTau 217 Plasma-test voor gebruik op het volledig geautomatiseerde LUMIPULSE® G immunoassay-platform in de Canadese markt. "De goedkeuring van de Lumipulse G NfL Blood- en Lumipulse G pTau 217 Plasma-testen voor kl...

GHENT, Belgien und TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. und ihre 100-prozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass Health Canada Lizenzen für Medizinprodukte der Klasse II (MDL) für den Lumipulse G NfL-Bluttest und den Lumipulse G pTau 217 Plasma-Assay für den Einsatz auf der vollautomatischen LUMIPULSE® G Immunoassay-Plattform auf dem kanadischen Markt erteilt hat. „Die Zulassung des Lumipulse G NfL-Bluttests und des Lumipulse G pTau 217 Plasma-Assays für den k...

比利時根特和東京--(BUSINESS WIRE)--(美國商業資訊)-- H.U. Group Holdings Inc.及其獨資子公司Fujirebio今日宣布，加拿大衛生部已針對「Lumipulse G NfL血液檢測」及「Lumipulse G pTau 217血漿檢測」核發II類醫療器材許可證（MDL），允許這兩項檢測在加拿大市場於全自動LUMIPULSE® G免疫分析平台上使用。 「Lumipulse G NfL血液檢測與Lumipulse G pTau 217血漿檢測在加拿大獲得臨床使用批准，標誌著我們在實現『讓全球更多的臨床醫師與病患能夠獲取可靠且具臨床意義的血液生物標記』這一使命上，又邁出了重要一步。」Fujirebio Europe N.V.執行長Christiaan De Wilde表示，「作為神經學診斷領域的先驅，Fujirebio將持續致力於透過創新且全自動化的檢測解決方案，提升病患照護品質。」 此次獲批進一步增強了Fujirebio神經系統疾病診斷產品的綜合布局，擴大了高品質生物標記解決方案的覆蓋範圍，旨在為病患全病程中的臨床決策提供支援。憑藉著不斷擴展的血...

比利时根特和日本东京--(BUSINESS WIRE)--(美国商业资讯)-- H.U. Group Holdings Inc.及其全资子公司Fujirebio今日宣布，加拿大卫生部已向Lumipulse G NfL血液检测试剂及Lumipulse G pTau 217血浆检测试剂颁发II类医疗器械许可证（MDL），准许两项检测试剂在加拿大市场搭载全自动LUMIPULSE® G免疫分析平台使用。 Fujirebio Europe N.V.首席执行官Christiaan De Wilde表示：“Lumipulse G NfL血液检测试剂和Lumipulse G pTau 217血浆检测试剂获准在加拿大用于临床检测，是我们朝着使命迈进的又一重要一步——让全球更多临床医生和患者能够获得可靠、具有临床意义的血液生物标志物检测。作为神经系统诊断领域的先驱，Fujirebio将继续致力于以创新的全自动检测解决方案推动患者照护水平不断提升。” 此次获批进一步完善了Fujirebio全面的神经系统诊断产品组合，扩大了高质量生物标志物解决方案的可及性，为患者全程诊疗中的临床决策提供支持。Fujirebi...

GANTE, Bélgica y TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. y su subsidiaria Fujirebio anunciaron hoy que Health Canada otorgó licencias de dispositivos médicos Clase II para los ensayos Lumipulse G NfL Blood y Lumipulse G pTau 217 Plasma, destinados a utilizarse en la plataforma de inmunoensayo totalmente automatizada LUMIPULSE® G en el mercado canadiense. "La autorización de los ensayos Lumipulse G NfL Blood y Lumipulse G pTau 217 Plasma para uso clínico en Canadá representa un nuevo pa...

GHENT, Belgio e TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. e la sua azienda interamente controllata Fujirebio oggi hanno annunciato che Health Canada ha rilasciato autorizzazioni per dispositivi medici (MDL) di Classe II per i test Lumipulse G NfL Blood e Lumipulse G pTau 217 Plasma per l'uso sulla piattaforma per test immunologici interamente automatizzata LUMIPULSE® G sul mercato canadese. "L'autorizzazione dei test Lumipulse G NfL Blood e Lumipulse G pTau 217 Plasma per uso clinico in...

GHENT, Bélgica e TÓQUIO--(BUSINESS WIRE)--H.U. A Group Holdings Inc. e sua subsidiária integral Fujirebio anunciaram hoje que a Health Canada concedeu Licenças de Dispositivo Médico (MDL) de Classe II para os ensaios Lumipulse G NfL Blood e Lumipulse G pTau 217 Plasma, para uso na plataforma de imunoensaio totalmente automatizada LUMIPULSE® G no mercado canadense. "A aprovação dos ensaios Lumipulse G NfL Blood e Lumipulse G pTau 217 Plasma para uso clínico no Canadá representa mais um passo imp...

ATLANTA & TORONTO--(BUSINESS WIRE)--Euna Solutions®, a leading provider of purpose-built, cloud-based software for the public sector, today announced explorer and technology entrepreneur Sam Cossman as the keynote speaker for Eunaverse 2026, Euna's annual customer conference taking place September 14–16, 2026, at the Hilton Austin in Austin, Texas. Cossman is known for using emerging technology to explore some of the world’s most extreme and inaccessible environments. He has led expeditions int...

LONDON--(BUSINESS WIRE)--  TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Oberon AIM VCT plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer   2. Reason for the notification (please mark the appropri...